Topic Archives: NASH

Comments

  • Avatar

    #NASH $CWBR What a useful chart! I like information presented in this form. Thanks for posting Ben....

  • Gr8Full!

    #Idea > Designate a $TWTR coordinator. $TWTR pt raised to $50 per @odbroi this a.m. $$GLMD up 293% NASH $NAKD up ...

  • Gr8Full!

    $CWBR 8K > CohBar to Present CB4211 Novel Mechanism of Action at American Diabetes Association 78th Scientific Sessions...

  • Avatar

    $CWBR What?? Insider control 40.6 % 150 pending and issued patents---despite what you read here patents mean som...

  • Gr8Full!

    $CWBR (vow) 2nd Annual NASH Investor Conference 3/19/18 ManagersH.C. Wainwright St Regis Hotel--2 E 55th St NY. 1...

  • Gr8Full!

    "JMP $ENTA increasing PT 110 majority of our valuation has now shifted to pipeline, with ~$10/sh for HCV royalties; ~$86...

  • Avatar

    $vktx coyote vktx was simply a trade call as I have heard of potential safety issues with Viking’ Nash drug known to e...

  • Avatar

    $VKTX np Is anyone interested in VIking Therapeutics? Back in December PGATHUA wrote the following: $VKTX This s...

  • Avatar

    He's a tad busy to re-roof 5 houses on your schedule. His NV plant won't be completed for years, so take a look at it th...

  • Dr. KSS MD PhD

    First peptide to enter clinic mid 1028. Activity read-out early 2019 with regard to NASH and to obesity. After 50 we ...

  • SoGiAm

    A #Glance at Finviz.com this day 20180117 https://finviz.com/ icker Last Change Volume Signal RCON 3.03 77.71% 46088...

  • Dr. KSS MD PhD

    Hi Alex! I am thrilled that a person of your stature and expertise is here, and you are most welcome among us. I'm at yo...

  • SoGiAm

    Regarding $ATNM, tiny position - The main culprit of failure so far for this equity still wears his C-Suit and hat. Sh...

  • Avatar

    $CWBR Because CWBR has no competition when CWBR does a JV in for example the NASH area the up front payment by the JV p...

  • JohnM

    CWBR - Possible second-best performer. Best of breed drug for NASH will go into clinic later this year. Sheds obese body...

  • Avatar

    $AKAO NP Achaogen price target lowered to $27 from $31 at SunTrust SunTrust analyst Edward Nash lowered his price t...

  • Dr. KSS MD PhD

    After Friday's lurid selloff, $APTO, $BLPH, $AUPH and $HALO look like genuine bargains to me. In measured tones, ditto f...

  • Dr. KSS MD PhD

    Which is why, for now, CohBar is confining its R and D efforts exclusively to mitochondrially-elaborated peptides for sp...

  • SoGiAm

    #Private - NorthSea Therapeutics secures €25 million funding for clinical development of promising NASH drug 12 Dec...

  • SoGiAm

    TOP STORIES $PLUR http://e.endpointsnews.com/t/ViewEmail/t/47C303966BB52CF5/2F80028A944F69C925D77A725F39070E #ASH17:...

  • Avatar

    $MDGL NP ll.com: Madrigal Pharmaceuticals price target raised to $170 from $82 at Roth Capital Roth Capital analys...

  • Avatar

    $VKTX This stock might be a good trading (or investing if Doc gives his blessing) opportunity for the gummies. Their NA...

  • Avatar

    $MDGL $ESPR MDGL Achieves Primary Endpoint in Patients with NASH. https://finance.yahoo.com/news/madrigal-mgl-3196-ac...

  • Avatar

    $MDGL NP Madrigal's MGL-3196 achieves primary endpoint in Phase 2 clinical trial Madrigal Pharmaceuticals announced...

  • SoGiAm

    #ZKSS savez our #ars again! :-) $CWBR "another one bites the dust" $GALT fails in #NASH https://twitter.com/fezziwig20...

  • Avatar

    Thanks. I'm showing my ignorance. That is what I originally began to search for, but then thought I was wrong and change...

  • Avatar

    I have been trying to find information on NASH 2017 conference. I thought it was in December in the next week or so, but...

  • Dr. KSS MD PhD

    As regards the comments about fat intake and mitochondrial function, I think this is murkier than some claims on the int...

  • Dr. KSS MD PhD

    Fatty liver linked to a shrinking brain Reuters Health News Fatty liver disease that is not related to excess drinking...

  • Avatar

    $MDRL NP Madrigal Pharmaceuticals price target raised to $82 from $62 at Roth Capital Roth Capital analyst Yasmee...

  • Avatar

    $MDRL NP Madrigal Pharmaceuticals initiated with a Buy at H.C. Wainwright; tgt $54 -- Novel mechanism central to...

  • Dr. KSS MD PhD

    Interesting points, Miceal. There's always a drive in medicine to quantify, to offload clinical decision onto assays and...

  • Avatar

    I was about to post the following, when I saw your post, so not inserting myself into this conversation, but this seems ...

  • Avatar

    Doc, are you saying that after insulin resistance appears, NASH is difficult to reverse just by changing diet and exerci...

  • Dr. KSS MD PhD

    I regard the Occam's razor explanation as insulin resistance that is acquired, although there are certain ethnicities wi...

  • SoGiAm

    #NoBullying @StockGumshoe #TickedOFF #NASH $CWBR TDfreak! Geaux2TickedOFF https://www.stockgumshoe.com/2015/04/microblog...

  • SoGiAm

    $NASH - $GNFT np, $MDGL np, $CWBR - 3xOW edit in or add......

  • SoGiAm

    $CWBR OW - CohBar, Inc. Announces Third Quarter 2017 Financial Results MENLO PARK, Calif., Nov. 13, 2017 (GLOBE NEWS...

  • Avatar

    $CWBR $MDGL Big Difference Long CWBR NP MDGL-considering short-in middle of due diligence https://twitter.com/fezzi...

  • Avatar

    $MDGL reports Q3 results (11/09) Madrigal Pharmaceuticals (MDGL) was briefly discussed on this forum as a potential c...

  • Avatar

    $ABEO LONG Abeona Therapeutics initiated with a Buy at SunTrust; tgt $26 com: Abeona Therapeutics initiated with ...

  • Dr. KSS MD PhD

    Hi hedgeclipper.....thank you for your wonderful question. I like you already. You and I shall get along fine. Think of...

  • Dr. KSS MD PhD

    I regard CohBar's MOTS-C based peptides for NASH as best of breed: https://pbs.twimg.com/media/DNJNouVWsAAkFzX.jpg:larg...

  • Avatar

    CWBR Another mixed bag results on the quest for NASH treatment. This time from GILD http://www.biopharmadive.com/n...

  • Avatar

    $CWBR thanks DR. cant wait til wallstreet and big nash players figure it out and volume starts pouring in and maybe a pa...

  • Dr. KSS MD PhD

    Figure 2, panel C of the poster says it all. What you see when you look at NASH histology slides is pink (eosin.....live...

  • Dr. KSS MD PhD

    Jim....it IS good news. People are digesting it. Unfortunately they worded their data in such a way that it's hard here ...

  • Dr. KSS MD PhD

    The agent potency described in the CohBar poster is quite quite compelling; I suspect shares are selling off because inv...

  • Avatar

    $CWBR at $AASLD CohBar Presents Preclinical Data on CB4209/CB4211 Program for NASH at the AASLD Liver Meeting® 2017 ...

  • Avatar

    $CWBR Long CohBar, Inc. (OTCQX:CWBR) (TSXV:COB.U), an innovative biotechnology company focused on developing mitoch...

  • Avatar

    imagine a couple million shares traded in this thing in a day after NASH with everyone chasing it higher.. thats what i ...

  • Avatar

    $RBC highlights $CWBR among "the most impactful posters" @AASLD17 for early #NASH Rx Doc will be attending. conferenc...

  • Avatar

    $ZFGN $CWBR Sorry Doc I disagree. I hope I do not own a single Biotech that will operate at a profit. My hope is they wi...

  • Avatar

    $CWBR (long) I was confused by this tweet: "$CWBR will target #AD #AMD #NASH, ASHD, Diabetes, Obesity, & Stati...

  • Avatar

    Jon Stern 9:35 AM (8 hours ago) to me Dear Jason – We appreciate your inquiry. As you probably know, we are ...

  • Dr. KSS MD PhD

    A NASH partnership announcement, if there is to be one, could come at any time. During our visit to CohBar, they'd clear...

  • Avatar

    Hello, I have a few questions ... 1) When do they hope to have a NASH Partner? We have stated that we have initi...

  • Avatar

    $CWBR Finance itself via joint venture agreements with upfront fees--hopefully $ 50 to $ 100 million for NASH. Mutiple J...

  • Avatar

    $CWBR - Thanks, Peter. For anyone contemplating taking a position in CohBar, or bolstering your confidence if already co...

  • Dr. KSS MD PhD

    Logging in from Moscow. Greetings everybody. Other endpoints of the study include lipoprotein profile and insulin resist...

  • Avatar

    $CWBR COHBAR INC (OTCMKTS:CWBR) Pushing The Limits Of Life Through Mitochondria Research 10/14/17 Mitochondria ...

  • Dr. KSS MD PhD

    The point here is that even though there IS a reasonable shot at ICPT's agent showing efficacy in a NASH trial, no one c...

  • SoGiAm

    Welcome TO the Frightening, (the 13th ya know!) #Gr8Gummune Emo! As $ICPT's probability of successfully Rxing #NASH d...

  • Avatar

    $CWBR Hi Doc -- if you would indulge my curiosity for a moment, one question that comes to mind is that since 99% of ...

  • Avatar

    Here is the near term $CWBR catalyst The company is set to make a presentation at The Liver Meeting 2017 slated for ...

  • Avatar

    $CWBR We can all help with the due diligence process by calling the investor relations person for CohBar Clay Chase and...

  • Avatar

    $CWBR CohBar Cleveland Due Diligence Assistance New CohBar Elevator Pitch ---If you have suggestions how this can be ...

  • Avatar

    $CWBR Obesity Nash Go look at Page 16 Reduces Liver Fat Look at slide 3 CohBar CB4209--Doc almost fell out of his ...

  • SoGiAm

    $ESPR Oct 17,17 - Esperion to Host Analyst and Investor Day Event on October 17 http://investor.esperion.com/releasedet...

  • Avatar

    $KSS, long In theory, we have a thousand better things to talk about, but I will allow myself this one post (hopefully ...

  • Avatar

    So are you saying Gilead paid too much for a Phase 1 Nash asset of $ 1.2 Billion? Or the companies that put $ 50 to $ 10...

  • Avatar

    $CWBR This is what Doc was talking about in the $CWBR conference call--What do you think the impact will be on biotec...

  • Avatar

    $CWBR CohBar Cleveland Due Diligence Assistance Summary of Articles and Videos to Assist in Due Diligence—24 pages...

  • Avatar

    $CWBR CohBar Cleveland Due Diligence Assistance Summary of Articles and Videos to Assist in Due Diligence https://...

  • Avatar

    $Top three areas of innovation in biotech. A European perspective https://labiotech.eu/biotech-innovation-powerhouse-ph...

  • Dr. KSS MD PhD

    For Zimmyzee and others pertaining to ProMetics. I digesred much information about the antifibrotic lead drug candida...

  • Dr. KSS MD PhD

    Earlier this year, we warned you in these pages that this study for NASH would fail. And we sold all Allergan shares in ...

  • Dr. KSS MD PhD

    Why has Corbus refused to evaluate anabasum in human NASH? That's the most widespread chronic parenchymal inflammatory c...

  • Dr. KSS MD PhD

    Hi Julie....welcome to this community and thanks for posting. Intercept was actually the subject of my first column for ...

  • Dr. KSS MD PhD

    In my view, Tobira is pure strike-out for NASH, but company wants to phase 3 the agent anyway. How can placebo be an app...

  • Dr. KSS MD PhD

    It tends to NASH out livers swiftly, too....

  • Dr. KSS MD PhD

    Basically, it's hard to find nausea that can break through Zyprexa. My simplistic way of thinking of it is that it's the...

  • SoGiAm

    #CYDY long - CytoDyn Provides Update on Enrollment in its Pivotal Phase 2b/3 HIV Combination Trial http://ir.cytodyn.com...

  • Avatar

    NASH http://reliawire.com/urmc-099-liver-damage/...

  • Dr. KSS MD PhD

    Hi jking: the more things change the more they stay the same. In 1998, I was having lunch with Cynthia, a hepatology res...

  • Avatar

    "Becoming your own Banker", by Nelson Nash. Worth a read....

  • Avatar

    $GILD Long I have a confession that I have been building up a $GILD position over the past month. If anyone cares wh...

  • Dr. KSS MD PhD

    Do I believe anabasum does something? Yes. But my biggest concern is that the biggest utility for this type of drug in c...

  • SoGiAm

    $CLRB long - Daniel, believe Tom may have confused with $CRBP From June 7 - Long $CRBP. Some scientific doubts have e...

  • Dr. KSS MD PhD

    That's the upshot, yes. In general, I feel that one should avoid investing in medical diagnostics. We've found two super...

  • Dr. KSS MD PhD

    I'm assuming this question is to me. It's been years since I've had a positive outlook on Gilead. It is not investment-w...

  • Dr. KSS MD PhD

    I personally won't be at the shareholder meeting. We've spoken little of GNFTF because it has become an increasingly tou...

  • Avatar

    $linling doctrine. No link, but it is a point she has made periodically, most recently with regard to $ARTH. I think ...

  • Dr. KSS MD PhD

    Thanks Sogiam. I was booking tickets earlier tonight. Planning to be there. May also try to take in the Gemphire NASH sy...

  • SoGiAm

    #NASH - Progression from #NALFD to #NASH is by regulated by CD44. This could be a #novel #therapeutic #target http://ww...

  • Dr. KSS MD PhD

    Akari very much feels it is right place right time as regards having discovered the anti-LTB4 activity of coversin. LTB4...

  • Avatar

    NASH in Reuters headlines... INSIGHT-NASH: The next untapped pharma market gives investors many options 1:00 AM ET, ...

  • SoGiAm

    $GNFT np - NASH frontrunner Genfit says phase 3 enrollment delayed by up to 6 months http://www.fiercebiotech.com/biotec...

  • Avatar

    Pharmacological inhibition of PPARγ is therapeutically effective in a preclinical murine model of steatosis-associated ...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch